TNYA Jun 2024 5.000 call
| Previous close | 0.1000 |
| Open | 0.0500 |
| Bid | 0.0000 |
| Ask | 2.4500 |
| Strike | 5.00 |
| Expiry date | 2024-06-21 |
| Day's range | 0.0500 - 0.0500 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.42k |
GlobeNewswireTenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Chief Executive Officer, will participate in the TD Cowen Genetic Medicines & RNA Summit on Friday, June 21, 2024, at 11:20 am ET. The live presentation will be webcast and may be accessed fro
Simply Wall St.We're Keeping An Eye On Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
- GlobeNewswire
Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Initial Data from Ongoing MyPEAK™-1 Phase 1b of TN-201 Expected in Second Half of 2024 Clinical Sites Activated for RIDGE™-1 Phase 1b Clinical Trial of TN-401 Announced Cost Containment Measures in Alignment with Focus on Generating Data from Clinical-Stage Gene Therapy Programs Raised $47 Million Net Proceeds in First Quarter Financing; Current Cash Runway into Second Half of 2025 SOUTH SAN FRANCISCO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-
